Ernexa Therapeutics Inc. Derivative Liability, Noncurrent
Ernexa Therapeutics Inc. (ERNA) had Derivative Liability, Noncurrent of $1.00 thousand as of 2024-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-03-13
- 2024-12-31: Derivative Liability, Noncurrent $1.00K.
- 2024-09-30: Derivative Liability, Noncurrent $10.46M.
- 2024-06-30: Derivative Liability, Noncurrent $50.00K.
- 2024-03-31: Derivative Liability, Noncurrent $186.00K.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2024-12-31 | $1.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | $10.46M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $50.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $186.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $116.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $165.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $185.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $376.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $331.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $633.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $2.52M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $13.31M 10-Q · filed 2022-07-01 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |